Company Profile: Neuro Pharmalogics, Inc.

CED Life Science Conference 2017 - Lightning Round

Sub-sector: Biotech and Pharmaceutical                                                              
Year Founded: 2016

COMPANY PROFILE
We are a biopharmaceutical company that is focused on developing/commercializing innovative therapies for people with rare (orphan) neurological diseases treatable by PKG signaling modification: Hemiplegic Migraine Neural Trauma (TBI, Spinal shock) Ischemic, Epileptic and other Neurological Conditions.

FOUNDERS/MANAGEMENT TEAM
David Muth, President and CEO
Ken Dawson-Scully MSc PhD, CSO
Stacee Caplan MS PhD, Director of Research
Michael L. Corrado MD, Clinical/Regulatory Affairs
Ben Thornton PhD, Preclinical R&D

KEY MILESTONES TO DATE

  • Funding: Self funding by board members
  • Selected as a Tech Runway (FAU) company
  • Selected as a finalist for the 2016 BioFlorida Pitch Competition
  • Licensed patents
  • Selected a lead compound NP-101 PP@A inhibitor
  • Completed Initial work in insects, advancing Preclinical work in mammals ongoing

CONTACT
David Muth
dmuth@neuropharmalogics.com
Boca Raton, FL

Learn more about the CED Life Science Conference.